A Clinical study to which Anti-emetic effect of 5-HT3RA is evaluated by using MAT in HEC for gastric cancer.

A Clinical study to which Anti-emetic effect of 5-HT3RA is evaluated by using MAT in HEC for gastric cancer. - A Clinical study to which Anti-emetic effect of 5-HT3RA is evaluated by using MAT in HEC for gastric cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004135

Enrollment

Registered

2010-09-02

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

The aloxi 0.75mg is administered before the anti-cancer drug of day1 is administered.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Gastric Cancer 2) Patient of administering schedule when 5- HT3RA is being administered for HEC. 3) 20 years old or more 4) Performance Status(ECOG scale): 0-2 5) Adequate organ function for enrollment. 6) Necessary data can be accumulated. 7) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Hypersensitivity or severe drug allergy for Aloxi or other 5-HT3RA. 2) Hypersensitivity or severe drug allergy for dexamethasone. 3) Any other patient whom the physician in charge of the study judges to be not eligible

Design outcomes

Primary

Measure	Time frame
The level of each observation point of the nausea and vomiting before and after 5- HT3RA change is evaluated by MAT.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026